Skip to Content

Join the 'Exelon' group to help and get support from people like you.

Exelon News

There's Still No Proven Way to Prevent Alzheimer's

Posted 19 Dec 2017 by Drugs.com

MONDAY, Dec. 18, 2017 – Medical science has failed to prove that any treatment, therapy or brain exercise can help prevent dementias such as Alzheimer's disease, an extensive new review has concluded. No medications, over-the-counter remedies or brain training programs have been proven in solid clinical trials to ward off dementia, researchers with the Minnesota Evidence-Based Practice Center in ...

Special Training Plus Medication Might Help People With Advanced Alzheimer's

Posted 18 Jul 2017 by Drugs.com

TUESDAY, July 18, 2017 – People with advanced Alzheimer's can relearn some basic skills when they receive special training along with medication, a small study suggests. The research, which included 20 Alzheimer's patients, tested a program that combines specialized "memory coaching" with other services – including training and support groups for family caregivers. Researchers found that adding ...

Dozens of Potential Alzheimer's Meds in the Pipeline

Posted 18 Jul 2017 by Drugs.com

TUESDAY, July 18, 2017 – Nearly three dozen new Alzheimer's drugs may begin clinical trials in the next five years, researchers say. That includes 27 drugs in phase 3 clinical trials, which are later in the drug review process. It also includes eight drugs in phase 2 clinical trials, according to an analysis by ResearchersAgainstAlzheimer's (RA2) investigators, an UsAgainstAlzheimer's network. ...

Dementia Drug May Lower Risk of Falls Among Parkinson's Patients

Posted 13 Jan 2016 by Drugs.com

TUESDAY, Jan. 12, 2016 – A widely used dementia drug shows potential in reducing the risk of falls among Parkinson's patients, new research suggests. "With the degeneration of dopamine-producing nerve cells, people with Parkinson's often have issues with unsteadiness when walking. As part of the condition, they also have lower levels of acetylcholine, a chemical which helps us to concentrate – ...

Dementia Meds May Lead to Harmful Weight Loss: Study

Posted 3 Aug 2015 by Drugs.com

MONDAY, Aug. 3, 2015 – A class of drugs widely used to treat dementia – called cholinesterase inhibitors – could cause harmful weight loss in some patients, a new study suggests. These medications include Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine). "Our study provides evidence in a large, real-world population that cholinesterase inhibitors may contribute to ...

Novartis Exelon Patch Now FDA Approved to Treat Patients Across all Stages of Alzheimer's Disease

Posted 30 Jun 2013 by Drugs.com

EAST HANOVER, N.J., June 27, 2013 /PRNewswire/ – The US Food and Drug Administration (FDA) has expanded the approved indication for Exelon Patch (rivastigmine transdermal system) to include the treatment of people with severe Alzheimer's disease (AD) with Exelon Patch 13.3mg/24h.  Exelon Patch is now the first and only transdermal therapy approved to treat patients with mild, moderate and severe ...

Higher Dose of Novartis Drug Exelon Patch Approved By FDA for Patients With Mild to Moderate Alzheimer's Disease

Posted 4 Sep 2012 by Drugs.com

EAST HANOVER, N.J., Sept. 4, 2012 /PRNewswire/ – The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease. The new 13.3 mg/24 h dosage strength of Exelon Patch provides physicians with a new treatment option for patients who are experiencing a decline in overall function ...

Ask a Question

Further Information

Related Condition Support Groups

Alzheimer's Disease, Parkinson's Disease

Exelon Patient Information at Drugs.com